Cargando…
Kimyrsa and Orbactiv – A Tale of Two Formulations
Kimyrsa is a new formulation (NF) of the original formulation of oritavancin ([OF] Orbactiv). Comparatively, the obvious benefit with this product is the shortened infusion time and flexibility with solution compatibility, but otherwise maintains a similar pharmacokinetic and microbiologic profile....
Autores principales: | Jackson, Brittany T, Cluck, David B, Henao-Martínez, Andrés F, Chastain, Daniel B |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10010140/ https://www.ncbi.nlm.nih.gov/pubmed/36923104 http://dx.doi.org/10.2147/DDDT.S324285 |
Ejemplares similares
-
Kimyrsa, An Oritavancin-Containing Product: Clinical Study and Review of Properties
por: Hoover, Randall K, et al.
Publicado: (2022) -
249. Characteristics and outcomes of cryptococcosis among patients with COVID-19 compared to non-COVID-19 controls
por: Chastain, Daniel B, et al.
Publicado: (2022) -
Cerebral Cryptococcomas: A Systematic Scoping Review of Available Evidence to Facilitate Diagnosis and Treatment
por: Chastain, Daniel B., et al.
Publicado: (2022) -
Cryptococcosis in a patient with multiple myeloma receiving pomalidomide: a case report and literature review
por: Chastain, Daniel B., et al.
Publicado: (2022) -
Distribution of age, sex, race, and ethnicity in COVID-19 clinical drug trials in the United States: A review
por: Chastain, Daniel B., et al.
Publicado: (2022)